Acumen Pharmaceuticals, Inc. (ABOS) stock
ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 2/30
$0.19−0.04 (-15.51%)
Close on Nov 18, 2026Market cap $14.06MP/E –Yield –
Acumen Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Acumen Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $85.93M, down 27.7% year over year. For fiscal 2025 it was $104.89M, up 11.8% from the year before. The highest annual figure on record is $104.89M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.89M | +11.8% |
| FY2024 | Dec 31, 2024 | $93.80M | +121.7% |
| FY2023 | Dec 31, 2023 | $42.32M | +30.8% |
| FY2022 | Dec 31, 2022 | $32.36M | +163.0% |
| FY2021 | Dec 31, 2021 | $12.31M | +53.9% |
| FY2020 | Dec 31, 2020 | $8.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $21.11M | -3.9% |
| Q2 FY2026 | Jun 30, 2026 | $27.81M | -25.1% |
| Q1 FY2026 | Mar 31, 2026 | $16.48M | -34.8% |
| Q4 FY2025 | Dec 31, 2025 | $20.53M | -40.6% |
| Q3 FY2025 | Sep 30, 2025 | $21.97M | -19.4% |
| Q2 FY2025 | Jun 30, 2025 | $37.13M | +90.1% |
| Q1 FY2025 | Mar 31, 2025 | $25.27M | +103.0% |
| Q4 FY2024 | Dec 31, 2024 | $34.57M | +160.1% |
| Q3 FY2024 | Sep 30, 2024 | $27.25M | +143.7% |
| Q2 FY2024 | Jun 30, 2024 | $19.53M | +113.9% |
| Q1 FY2024 | Mar 31, 2024 | $12.45M | +42.9% |
| Q4 FY2023 | Dec 31, 2023 | $13.29M | +23.7% |
| Q3 FY2023 | Sep 30, 2023 | $11.18M | +34.5% |
| Q2 FY2023 | Jun 30, 2023 | $9.13M | +24.8% |
| Q1 FY2023 | Mar 31, 2023 | $8.71M | +45.6% |
| Q4 FY2022 | Dec 31, 2022 | $10.75M | +89.4% |
| Q3 FY2022 | Sep 30, 2022 | $8.31M | +361.6% |
| Q2 FY2022 | Jun 30, 2022 | $7.32M | +224.8% |
| Q1 FY2022 | Mar 31, 2022 | $5.99M | +132.2% |
| Q4 FY2021 | Dec 31, 2021 | $5.67M | +452.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.80M | -39.9% |
| Q2 FY2021 | Jun 30, 2021 | $2.25M | +17.0% |
| Q1 FY2021 | Mar 31, 2021 | $2.58M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.03M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.99M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.93M | – |
See a number that looks wrong?